Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-32
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network I. NCCN clinical practice guidelines in oncology: non-Hodgkins lymphomas. Fort Washington, PA: NCCN; 2016
   Google Scholar
• National Cancer Institute. SEER Stat Fact Sheets: Non-Hodkins Lymphoma.Data years for 1975-2013. Bethesda, MD. Accessed July 2017.
   Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study. J Clin Oncol 2015;33:2516-22
   PubMed Web of Science ®Google Scholar
• Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clinic Proc 2005;80:1087-97
   PubMed Web of Science ®Google Scholar
• Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-7
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-71
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009;27:1607-14
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-8
   PubMed Web of Science ®Google Scholar
• Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21-7
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-10
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010;116:106-14.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016;17:1081-93
   PubMed Web of Science ®Google Scholar
• Cheson BD, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN study. Blood 2016;128:615
   Google Scholar
• Food and Drug Administration. Gazyva Package Insert 2017 [cited 2017]. Silver Spring, MD. Available from: www.gene.com/download/pdf/gazyva_prescribing.pdf [Last accessed July 2017]
   Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 2016
   Google Scholar
• Genentech Inc. Data on file. San Francisco, CA, 2017
   Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202-8
   PubMed Web of Science ®Google Scholar
• Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2018.
   Google Scholar
• Centers for Medicare & Medicaid Services. CY 2016 Physician Fee Schedule Final Rule. Baltimore, MD, 2016
   Google Scholar
• Pettengell R, Donatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol 2008;19:570-6
   PubMed Web of Science ®Google Scholar
• Wild D, Walker M, Pettengell R, et al. PCN62 utility elicitation in patients with follicular lymphoma. Value Health 2006;9:A294
   Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7
   PubMed Web of Science ®Google Scholar
• Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma. Technol Assess 2009;13 Suppl 2:41-8
   PubMed Web of Science ®Google Scholar
• Blommestein HM, Issa DE, Pompen M, Ten Hoor G, Hogendoorn M, Joosten P, Zweegman S, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. Eur J Haematol. 2014;92(5):398-406
   Google Scholar